WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, Vic., Australia; School of Applied Sciences, Monash University, Churchill, Vic., Australia.
Influenza Other Respir Viruses. 2013 Nov;7(6):904-8. doi: 10.1111/irv.12108. Epub 2013 Mar 29.
A minor viral population of oseltamivir-resistant A(H3N2) viruses (E119V neuraminidase mutation) was selected and maintained in a continually infected immunocompromised child following initial oseltamivir treatment. A subsequent course of oseltamivir given 7 weeks later rapidly selected for the E119V variant resulting in a near-pure population of the resistant virus. The study highlights the challenges of oseltamivir treatment of immunocompromised patients that are continually shedding virus and demonstrates the ability of the E119V oseltamivir-resistant virus to be maintained for prolonged periods even in the absence of drug-selective pressure.
奥司他韦耐药的 A(H3N2) 病毒（E119V 神经氨酸酶突变）的一小部分病毒群在初始奥司他韦治疗后，在持续感染的免疫功能低下的儿童中被选择和维持。7 周后给予的后续奥司他韦疗程迅速选择了 E119V 变异体，导致耐药病毒的近乎纯种群。该研究强调了奥司他韦治疗持续病毒排出的免疫功能低下患者的挑战，并证明了即使没有药物选择压力，E119V 奥司他韦耐药病毒也能够长时间维持。
